Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBT (2016 - 2025)

Coherus Oncology (CHRS) has disclosed EBT for 13 consecutive years, with -$46.3 million as the latest value for Q4 2025.

  • Quarterly EBT fell 0.55% to -$46.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$183.1 million through Dec 2025, up 15.45% year-over-year, with the annual reading at -$183.1 million for FY2025, 14.98% up from the prior year.
  • EBT hit -$46.3 million in Q4 2025 for Coherus Oncology, down from -$44.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$29.9 million in Q2 2021 to a low of -$172.9 million in Q1 2021.
  • Historically, EBT has averaged -$60.8 million across 5 years, with a median of -$47.5 million in 2024.
  • Biggest five-year swings in EBT: crashed 627.03% in 2021 and later soared 53.81% in 2023.
  • Year by year, EBT stood at -$45.7 million in 2021, then decreased by 28.85% to -$58.9 million in 2022, then plummeted by 35.32% to -$79.7 million in 2023, then surged by 42.13% to -$46.1 million in 2024, then fell by 0.55% to -$46.3 million in 2025.
  • Business Quant data shows EBT for CHRS at -$46.3 million in Q4 2025, -$44.5 million in Q3 2025, and -$44.9 million in Q2 2025.